Recent Advances in Molecular Biomarkers of Triple-Negative Breast Cancer

Hongmei Dai(Pingdingshan University)
Huizi Zhang(Pingdingshan University)
Xinyu Fu(Pingdingshan University)
Ran Li(Pingdingshan University)
Xianguang Bai(Pingdingshan University)

Abstract

Triple-negative breast cancer (TNBC) is a highly heterogeneous and aggressive subtype of breast cancer characterized by the absence of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) expression. Due to the lack of specific molecular targets, TNBC does not respond to conventional hormone or HER2-targeted therapies, posing a major challenge in breast cancer treatment. In recent years, molecular biomarkers have shown significant promise in the diagnosis, prognosis, and personalized treatment of TNBC. In-depth investigation of these biomarkers may lead to the development of more effective diagnostic and therapeutic strategies, ultimately improving patient outcomes. This review focuses on recent research progress concerning key molecular biomarkers in TNBC and explores their potential clinical applications, aiming to provide a theoretical basis for the advancement of precision therapy in TNBC.

Keywords

Triple-negative breast cancer; Molecular biomarkers; Precision therapy

References

Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017 [J]. CA Cancer J Clin, 2017, 67(1): 7-30.

Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods, and major patterns in GLOBOCAN 2012 [J]. International Journal of Cancer, 2015, 136(5): E359-86.

Li T, Mello-Thoms C, Brennan PC. Descriptive epidemiology of breast cancer in China: incidence, mortality, survival, and prevalence [J]. Breast Cancer Research and Treatment, 2016, 159(3): 395-406.

Siegel RL, Miller KD, Wagle NS, et al. Cancer Statistics, 2023 [J]. CA Cancer J Clin, 2023, 73(1): 17-48.

Gu ZQ, Zhu Y, Liu JY, et al. Tumor immune microenvironment of triple-negative breast cancer [J/OL]. Chemistry of Life, 2025: 1-11 [accessed 2025-04-12]. https://doi.org/10.13488/j.smhx.20240708.

Hu H, Tong K, Tsang JY, et al. Subtyping of triple-negative breast cancers: its prognostication and implications in diagnosis of breast origin [J]. ESMO Open, 2024, 9(4): 102993.

Jiang YZ, Ma D, Suo C, et al. Genomic and transcriptomic landscape of triple-negative breast cancers: subtypes and treatment strategies [J]. Cancer Cell, 2019, 35(3): 428-440.

Li Y, Zhang H, Merkher Y, et al. Recent advances in therapeutic strategies for triple-negative breast cancer [J]. J Hematol Oncol, 2022, 15(1): 121.

Lee DS, Kim SH, Suh YJ, et al. Clinical implication of p53 overexpression in breast cancer patients younger than 50 years with a triple-negative subtype who undergo a modified radical mastectomy [J]. Jpn J Clin Oncol, 2011, 41(7): 854-866.

Chae BJ, Bae JS, Lee A, et al. p53 as a specific prognostic factor in triple-negative breast cancer [J]. Jpn J Clin Oncol, 2009, 39(4): 217-224.

Biganzoli E, Coradini D, Ambrogi F, et al. p53 status identifies two subgroups of triple-negative breast cancers with distinct biological features [J]. Jpn J Clin Oncol, 2011, 41(2): 172-179.

Kim HS, Yom CK, Kim HJ, et al. Overexpression of p53 is correlated with poor outcome in premenopausal women with breast cancer treated with tamoxifen after chemotherapy [J]. Breast Cancer Res Treat, 2010, 121(3): 777-788.

Liang Y, Besch-Williford C, Benakanakere I, et al. Targeting mutant p53 protein and the tumor vasculature: an effective combination therapy for advanced breast tumors [J]. Breast Cancer Res Treat, 2011, 125(2): 407-420.

Su DW, Shi JY, Sheng Y, et al. P53, P16, Ki67 expression in triple-negative breast cancer and its prognostic significance [J]. Progress in Modern Biomedicine, 2009, 9(5): 894-895+913.

Meng D, Huang Y. Research advances in molecular markers of triple-negative breast cancer [J]. Chin J Breast Dis (Electr Ed), 2013, 7(5): 365-369.

Wang Y, Zhang T, Kwiatkowski N, et al. CDK7-dependent transcriptional addiction in triple-negative breast cancer [J]. Cell, 2015, 163(1): 174-186.

Li F. Discovery of survivin inhibitors and beyond: FL118 as a proof of concept [J]. Int Rev Cell Mol Biol, 2013, 305: 217-252.

Miles D, Gligorov J, Andre F, et al. Primary results from IMpassion130, a double-blind, placebo-controlled, randomized phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer [J]. Ann Oncol, 2021, 32: 994-1004.

Schmid P, Adams S, Rugo HS, et al. IMpassion130 Trial Investigators. Atezolizumab and Nab-Paclitaxel in advanced triple-negative breast cancer [J]. N Engl J Med, 2018, 379(22): 2108-2121.

Huang R, Li J, Pan F, et al. The activation of GPER inhibits cell proliferation, invasion, and EMT of triple-negative breast cancer via CD151/miR-199a-3p bio-axis [J]. Am J Transl Res, 2020, 12(1): 32-44.

Falkenberg N, Anastasov N, Schaub A, et al. Secreted uPAR isoform 2 (uPAR7b) is a novel direct target of miR-221 [J]. Oncotarget, 2015, 6(10): 8103-8114.

Liu S, Wang Z, Liu Z, et al. miR-221/222 activate the Wnt/β-catenin signaling to promote triple-negative breast cancer [J]. J Mol Cell Biol, 2018, 10(4): 302-315.

Li HY, Liang JL, Kuo YL, et al. miR-105/93-3p promotes chemoresistance and circulating miR-105/93-3p acts as a diagnostic biomarker for triple-negative breast cancer [J]. Breast Cancer Res, 2017, 19(1): 133.

Jiang L, Hermeking H. miR-34a and miR-34b/e suppress intestinal tumorigenesis [J]. Cancer Res, 2017, 77(10): 2746-2758.

Brogowska KK, Zajkowska M, Mroczko B. Vascular endothelial growth factor ligands and receptors in breast cancer [J]. J Clin Med, 2023, 12(6): 2412. DOI: 10.3390/jcm12062412.

Lev S. Targeted therapy and drug resistance in triple-negative breast cancer: the EGFR axis [J]. Biochem Soc Trans, 2020, 48(2): 657-665. DOI: 10.1042/BST20191055.

Jia L, Li G, Ma N, et al. Soluble POSTN is a novel biomarker complementing CA153 and CEA for breast cancer diagnosis and metastasis prediction [J]. BMC Cancer, 2022, 22(1): 760.

Fan Xie X, Shen Y, et al. The predictive value of preoperative serum neutrophil-to-lymphocyte ratio and tumor markers for early breast cancer patients: A retrospective study [J]. BMC Med, 2022, 101(32): e30011.

Xiao LS, Huang JL, Qiu SX, et al. Application value of CA153 and CEA in triple-negative breast cancer [J]. Guangdong Medical Journal, 2013, 34(13): 2029-2031.

Huang JL, Xiao LS, Zhou HC, et al. Diagnostic value of combined detection of serum CA153 and CEA in triple-negative breast cancer [J]. Chinese Journal of School Doctor, 2015, 29(5): 365-367.

Wang MJ, Zhang XJ, Li XX, et al. Expression of Cath-D and c-erbB-2 proteins in triple-negative breast cancer tissues and their correlation with lymph node metastasis and tumor markers [J]. Chinese Journal of Health Laboratory Technology, 2022, 32(23): 2888-2891.

Wei ZY, Zhan XM. Expressions of CXCL12, CXCR4 and E-cadherin in triple-negative breast cancer and their significance [J]. Journal of Shandong Medical College, 2013, 35(1): 17-20+81.

Ning J, Cheng G, He M, et al. Research progress on molecular markers in the diagnosis and treatment of triple-negative breast cancer [J]. Chin J Exp Diagn, 2025, 29(1): 101-109.

DOI: http://dx.doi.org/10.26549/jams.v8i1.24712